Abstract
Other chapters in this volume document the explosive recent advances in the genetic, neuroanatomical, and molecular pharmacological understanding of both the traditional and most prevalent D1* and D2L dopamine (DA) receptors and their recently discovered subtypes, D2S, D3, D4, and D5 (1–4). These advances promise to yield important contributions to clinical medicine. The localization of the genes for each of the identified DA receptors to specific regions of human chromosomes has stimulated many studies seeking evidence of genetic linkage in specific clinical conditions, particularly psychiatric and neurological disorders. There is also much progress in the development of DA receptor type-selective radioligands for application in postmortem neuropathological analyses and for positron emission tomography (PET) or single photon emission computed tomography (SPECT) of the brain for clinical applications. Finally, the discovery of the novel DA receptor types, and of apparently selective localization of types D3 and D4 to limbic or other nonextrapyramidal regions of forebrain, has stimulated a vigorous search for small-molecule ligands selective for these targets as potential psychotropic medicinal agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Civelli, O., Bunzow, J. R., and Grandy, D. K. (1993) Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. 32, 281–307.
De Keyser, J. (1993) Subtypes and localization of dopamine receptors in human brain. Neurochem. Int. 22, 83–93.
Gingrich, J. A. and Caron, M. G. (1993) Recent advances in the molecular biology of dopamine receptors. Ann. Rev. Neurosci. 16, 299–321.
Hall, H., Sedvall, G., Manusson, O., Kopp, J., Halldin, C., and Farde, L. O. (1994) Distribution ofD1 and D2 dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11, 245–256.
Baldessarini, R. J. (1996) Drugs and the treatment of psychiatric disorders, in Goodman and Gilman ‘s The Pharmacologic Basis of Therapeutics, 9th ed. ( Harden, W., Rudin, W., Molinoff, P. B., and Rall, T., eds.), McGraw-Hill, New York, pp. 399–459.
Baldessarini, R. J. (1996) Chemotherapy in Psychiatry: Principles and Practice,3rd ed. Harvard University Press, Cambridge, MA, in press.
Davis, K. L., Kann, R. S., Ko, G., and Davidson, M. (1991) Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148, 1474–1486.
Lieberman, J. A. and Koreen, A. R. (1993) Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophrenia Bull. 19, 371–429.
Meltzer, H. Y. and Stahl, S. M. (1976) The dopamine hypothesis of schizophrenia: a review. Schizophrenia Bull. 2, 19–76.
Reynolds, G. P. (1989) Beyond the dopamine hypothesis: the neurochemical pathology of schizophrenia. Br. J. Psychiatry 155, 305–316.
Seeman, P. (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1, 133–152.
Gessa, G. L. and Serra, G (eds.) (1990) Dopamine and Mental Depression. Pergamon, Oxford, UK.
Sunahara, R. K., Niznik, H. B., Weiner, D. M., Stormann, T. M., Brann, M. R., Kennedy, J. L., Gelernter, J. E., Rozmahel, R., Yang, Y., Israel, Y., Seeman, P., and O’Dowd, B. F. (1990) Human dopamine D, receptor encoded by an intronless gene on chromosome 5. Nature 347, 80–83.
Sherrington, R., Mankoo, B., Attwood, J., Kalsi, G., Curtis, D., Buetow, K., Povey, S., and Gurling, H. (1993) Cloning of the human dopamine D5 receptor gene and identification of a highly polymorphic microsatellite for the DRD5 locus that shows tight linkage to the chromosome 4p reference marker RAF-1P1. Genomics 18, 423–425.
Grandy, D. K., Litt, M., Allen, L., Bunzow, J. R., Marchionni, M., Makam, H., Reed, L., Megenis, R. E., and Civelli, O. (1989) The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a Taq-1 RFLP. Am. J. Hum. Genetics 45, 778–785.
Huage, X. Y., Grandy, D. R., Eubanks, J. H., Evans, G. A., Civelli, O., and Litt, M. (1991) Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 10, 527–530.
Lannfelt, L., Sokoloff, P., Martres, M.-P., Pilon, C., Giros, B., Jönsson, E., Sedvall, G., and Schwartz, J.-C. (1992) Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr. Genetics 2, 249–256.
Kennedy, J. L., Sidenberg, D. G., Van Tol, H. H., and Kidd, K. K. (1991) A Hinc-II RFLP in the human D4 dopamine receptor locus (DRD4). Nucleic Acids Res. 19, 5801, 5802.
Gelernter, J., Kennedy, J. L., Van Tol, H. H., Civelli, O., and Kidd, K. K. (1992) The D4 dopamine receptor (DRD4) maps to distal l 1p close to HRAS. Genomics 13, 208–210.
Van Tol, H. H., Bunzow, J. R., Guan, H.-C., Sunahara, R. K., Seeman, P., Niznik, H. B., and Civelli, O. (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350, 610–614.
Brett, P. M., Curtis, D., Robertson, M. M., and Gurling, H. M. (1995) The genetic susceptibility to Gilles de la Tourette syndrome in a large multiplex affected British kindred: linkage analysis excludes a role for the genes coding for dopamine Di, D2, D3, D4, D5 receptors, dopamine beta-hydroxylase, tyrosinase, and tyrosine hydroxylase. Biol. Psychiatry 37, 533–540.
Kendler, K. S. and Diehl, S. R. (1993) The genetics of schizophrenia: a current genetic-epidemiologic perspective. Schizophrenia Bull. 19, 261–285.
Kety, S. S., Wender, P. H., Jacobsen, B., Ingraham, L. J., Jansson, L., Faber, B., and Kinney, D. K. (1994) Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Arch. Gen. Psychiatry 51, 442–455.
Carpenter, W. T. and Buchanan, R. W. (1994) Schizophrenia. N. Engl. J. Med. 330, 681–690.
Crow, T. J. (1980) Molecular pathology of schizophrenia: more than one disease process. Br. Med. J. 280, 60–68.
Crow, T. J. (1986) The continuum of psychosis and its implications for the structure of the gene. Br. J. Psychiatry 149, 419–429.
Crowe, R. R. (1993) Candidate genes in psychiatry: an epidemiological perspective. Am J. Med. Genetics (Neuropsychiatric) 48, 74–77.
Taylor, M. A., Berenbaum, S. A., Jampala, V. C., and Cloninger, C. R. (1993) Are schizophrenia and affective disorder related? Preliminary data from a family study. Am. J. Psychiatry 150, 278–285.
Wright, I. and Woodruff, P. (1995) Aetiology of schizophrenia: a review of theories and their clinical and therapeutic implications. CNS Drugs 3, 126–144.
Loranger, A. W. (1981) Genetic independence of manic-depression and schizophrenia. Acta Psychiatr. Scand. 63, 444–452.
Kraepelin, E. (1919) Dementia Prcecox and Paraphrenia (Barclay, R. M. and Robertson, G. M., trans.), Livingstone, Edinburgh, UK.
Kraepelin, E. (1921)Manic-Depressive Insanity and Paranoia(Barclay, R. M. and Robertson, G. M., trans.), Livingstone, Edinburgh, UK.
Byerley, W., Plaetke, R., Jensen, S., Holik, J., Hoff, M., Myles-Worsley, M., Wender, P., Reimherr, F., Leppert, M., O’Connell, P., Lalouel, J., and White, R. (1991) Linkage analysis of six schizophrenia pedigrees with 150 DNA markers. Schizophrenia Res. 4, 274, 275.
Wildenauer, D. B., Schwab, S., Würl, D., Ertl, M., Ackenheil, M., Schmidt, S., Drews, B., Schmidt, F., Hallmayer, J., and Maier, W. (1991) Linkage analysis in schizophrenia: exclusion of 5g11—q13, 5q34-qtr, 11g22, 23, Xpter and chromosome 19 in 15 systematically ascertained European families. Am. J. Hum. Genetics 49 (Suppl. 4), 363.
Jensen, S., Plaetke, R., Holik, J., Hoff, M., Myles-Worsley, M., Leppert, M., Coon, H., Vest, K., Freedman, R., Waldo, M., Zhou, Q.-Y., Litt, M., Civelli, O., and Byerley, W. (1993) Linkage analysis of schizophrenia: the DI dopamine receptor gene and several flanking DNA markers. Hum. Heredity 43, 58–62.
Campion, D., d’Amato, T., Bastard, C., Laurent, C., Guedj, F., Jay, M., Dollfus, S., Thibault, F., Petit, M., Gorwood, P., Babron, M. C., Waksman, G., Martinez, M., and Mallet, J. (1994) Genetic study of dopamine D1, D2, and D4 receptors in schizophrenia. Psychiatry Res. 51, 215–230.
Cichon, S., Nöthen, M. M., Rietschel, M., Körner, J., and Propping, P. (1994) Single-strand conformation analysis (SSCA) of the dopamine Di receptor gene (DRD 1) reveals no significant mutation in patients with schizophrenia and manic-depression. Biol. Psychiatry 36, 850–853.
Dollfus, S., Campion, D., Vasse, T., Preterre, P., Laurent, C., d’Amato, T., Thibault, F., Mallet, J., and Petit, M. (1995) Association between dopamine DI, D2, D3, and D4 receptor genes and schizophrenia defined by 13 diagnostic systems. Schizophrenia Res. 15(1–2), 37, 38.
Coon, H., Byerley, W., Holik, J., Hoff, M., Myles-Worsley, M., Lannfelt, L., Sokoloff, P., Schwartz, J.-C., Waldo, M., Freedman, R., and Plaetke, R. (1993) Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees. Am. J. Hum. Genetics 52, 327–334.
Ravindranathan, A., Coon, H., DeLisi, L., Holik, J., Hoff, M., Brown, A., Shields, G., Crow, T., and Byerley, W. (1994) Linkage analysis between schizophrenia and a microsatellite polymorphism for the D5 dopamine receptor gene. Psychiatr. Genetics 4, 77–80.
Moises, H. W., Gelernter, J., Guiffa, L. A., Zarcone, V., Wetterberg, L., Civelli, O., Kidd, K. K., Cavalli-Szforza, L. L., Grandy, D. K., Kennedy, J. L., Vinogradov, S., Mauer, J., Litt, M., and Sjögren, B. (1991) No linkage between D2 dopamine receptor gene region and schizophrenia. Arch. Gen. Psychiatry 48, 643–647.
Sarkar, G., Kapelner, S., Grandy, D. K., Marchionni, M., Civelli, O., Sobell, J., Heston, L., and Sommer, S. S. (1991) Direct sequencing of the dopamine D2 receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural changes in the receptor. Genomics 11, 8–14.
Gill, M., McGuffin, P., Parfitt, E., Mant, R., Asherson, D., Collier, D., Vallada, H., Powell, J., Shaikh, S., Taylor, C., Sargeant, M., Clements, A., Nanko, S., Takazawa, N., Llewellyn, D., Williams, J., Whatley, S., Murray, R., and Owen, M. (1993) A linkage study of schizophrenia with DNA markers from the long arm of chromosome 11. Psychol. Med. 23, 27–44.
Su, Y., Burke, J., O’Neill, F. A., Murphy, B., Nie, L., Kipps, B., Bray, J., Skinkwin, R., Nuallain, M. N., MacLean, C., Walsh, D., Diehl, S. R., and Kendler, J. S. (1993) Exclusion of linkage between schizophrenia and the D2 dopamine receptor gene region of chromosome l l q in 112 Irish multiplex families. Arch. Gen. Psychiatry 50, 205–211.
Wang, Z., Black, D., Andreasen, N. C., and Crowe, R. R. (1993) A linkage study of chromosome l l q in schizophrenia. Arch. Gen. Psychiatry 50, 212–216.
Gejman, P. V., Ram, A., Gelernter, J., Friedman, E., Cao, Q., Pickar, D., Blum, K., Noble, E. P., Kranzler, H. R., O’Malley, S., Hamer, D. H., Whitsitt, F., Rao, P., DeLisi, L. E., Virkkunen, M., Linnoila, M., Goldman, D., and Gershon, E. S. (1994) No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. JAMA 271, 204–208.
Hattori, M., Nanko, S., Dai, X. Y., Fukuda, R., and Kazamatsuri, H. (1994) Mismatch PCR RFLP detection of DRD2 Ser311 Cys polymorphism and schizophrenia. Biochem. Biophys. Res. Commun. 202, 757–763.
Shaikh, S., Collier, D. A., Arranz, M., Crocq, M.-A., Gill, M., and Kerwin, R. (1995) Examination of the DRD2 (Ser-Cys) variant in schizophrenia. Schizophrenia Res. 15 (1–2), 48.
Nanko, S., Hattori, M., Ikeda, K., Sasaki, T., Kazamatzuri, H., and Kuwata, S. (1993) Dopamine D4 receptor polymorphism and schizophrenia. Lancet 341, 689, 690.
Wiese, C., Lannfelt, L., Kristbjarnarson, H., Yang, L., Zoega, T., Sokoloff, P., Ivarsson, O., Schwartz, J.-C., Moises, H. W., and Helgason, T. (1993) No evidence of linkage between schizophrenia and D3 receptor gene locus in Icelandic pedigrees. Psychiatry Res. 46, 69–78.
Sabaté, O., Campion, D., d’Amato, T., Martres, M. P., Sokoloff, P., Giros, B., Leboyer, M., Jay, M., Guedj, F., Thbault, F., Dollfus, S., Preterre, P., Petit, M., Bobron, M.-C., Waksman, G., Mallet, J., and Schwartz, J.-C. (1994) Failure to find evidence for linkage or association between the dopamine D3 receptor gene and schizophrenia. Am. J. Psychiatry 151, 107–111.
Crocq, M. A., Duval, F., Mayerova, A., Sokoloff, P., Mokrani, M. C., and Macher, J. P. (1995) Clinical and functional correlates of a dopamine D3 receptor polymorphism. Hum. Psychopharmacol. 10, 19–24.
Barr, C. L., Kennedy, J. L., Lichter, J. B., Van Tol, H. H., Wetterberg, L., Livak, K. J., and Kidd, K. K. (1993) Alleles at the dopamine D4 receptor locus do not contribute to the genetic susceptibility to schizophrenia in a large Swedish kindred. Am. J. Med. Genetics (Neuropsychiatric) 48, 218–222.
Debryn, A., Mandelbaum, K., Sandkuijl, L. A., Delvenne, V., Hirsch, D., Staner, L., Mendlewicz, J., and Van Broeckhoven, C. (1994) Nonlinkage of bipolar illness to tyrosine hydroxylase, tyrosinase, and D2 and D4 dopamine receptor genes on chromosome 11. Am. J. Psychiatry 151, 1202–1206.
Macciardi, F., Petronis, A., Van Tol, H. H., Marino, C., Cavallini, C., Smeraldi, E., and Kennedy, J. L. (1994) Analysis of the D4 dopamine receptor gene variant in an Italian schizophrenia kindred. Arch. Gen. Psychiatry 51, 288–293.
Rao, P. A., Pickar, D., Gejman, P. V., Ram, A., Gershon, E. S., and Gelernter, J. (1994) Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch. Gen. Psychiatry 51, 912–917.
Catalano, M., Nobile, M., Novelli, E., Nöthen, M. M., and Smeraldi, E. (1993) Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients. Biol. Psychiatry 34, 459–464.
Holmes, D., Brynjolfsson, J., Brett, P., Curtis, D., Pertursson, H., Sherrington, R., and Gurling, H. (1991) No evidence of a susceptibility locus predisposing to manic-depression in the region of the dopamine (D2) receptor gene. Br. J. Psychiatry 158, 635–641.
Blum, K., Noble, E. P., Sheridan, P. J., Montgomery, A., Ritchie, T., Jagadeeswaran, P., Nogami, H., Briggs, A. H., and Cohn, J. B. (1990) Allelic association of human dopamine D, receptor gene in alcoholism. JAMA 263, 2055–2060.
Noble, E. P., Blum, K., Ritchie, T., Montgomery, A., and Sheridan, P. J. (1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch. Gen. Psychiatry 48, 648–654.
Bolos, A. M., Dean, M., Lucas-Derse, S., Ramsburg, M., Brown, G. L., and Goldman, D. (1990) Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism. JAMA 264, 3156–3160.
Gelernter, J., O’Malley, S., Risch, N., Kranzler, H. R., Krystal, J., Merikangas, K., Kennedy, J. L., and Kidd, K. K. (1991) No association between an allele at the D2 dopamine receptor gene (DRD2) and alcoholism. JAMA 266, 1801–1807.
Parsian, A., Todd, R. D., Devor, E. J., O’Malley, K. L., Suarez, B. K., Reich, T., and Cloninger, C. R. (1991) Alcoholism and alleles of the human D2 dopamine receptor locus. Arch. Gen. Psychiatry 48, 655–663.
Noble, E. P. (1993) The D2 dopamine receptor gene: a review of association studies in alcoholism. Behay. Genetics. 23, 119–129.
Comings, D. E. (1994) The dopamine D2 receptor gene (DRD2) and neuropsychiatric disorders. CNS Drugs 1, 1–5.
Conneally, P. M. (1991) Association between the D2 dopamine receptor gene and alcoholism. Arch. Gen. Psychiatry 48, 664–666.
Devor, E. J. (1984) Complex segregation analysis of Gilles de la Tourette syndrome: further evidence for a major locus mode of transmission. Am. J. Hum. Genetics 36, 704–709.
Gelernter, J., Pakstis, A., Pauls, D. L., Kurlan, R., Grancher, S. T., Civelli, O., Grandy, D., and Kidd, K. K. (1990) Tourette syndrome is not linked to D2 dopamine receptor. Arch. Gen. Psychiatry 47, 1073–1077.
Gelernter, J., Kennedy, J. L., Grandy, D. K., Zhou, Q.-Y., Civelli, O., Pauls, D. L., Pakstis, A., Kurlan, R., Sunahara, R. K., Niznik, H. B., O’Dowd, B., Seeman, P., and Kidd, K. K. (1993) Exclusion of close linkage of Tourette’s syndrome to DI dopamine receptor. Am. J. Psychiatry 150, 449–453.
Landwehrmeyer, B., Mengod, G., and Palacios, J. M. (1993) Differential visualization of dopamine DZ and D3 receptor sites in rat brain: a comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur. J. Neurosci. 5, 145–153.
Lévesque, D., Diaz, J., Pilon, C., Martres, M.-P., Giros, B., Souil, E., Schott, D., Morgat, J.-L., Schwartz, J.-C., and Sokoloff, P. (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7[3H]hydroxyN,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. USA 89, 8155–8159.
Crocq, M. A., Mant, R., Asherson, P., Williams, J., Hode, Y., Mayerova, A., Collier, D., Lannfelt, L., Sokoloff, P., Gill, M., Macher, J. P., McGuffin, P., and Owen, M. J. (1992) Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J. Med. Genetics 29, 858–860.
Mant, R., Williams, J., Asherson, P., Parfitt, E., McGuffin, P., and Owen, M. J. (1994) Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. Am. J. Med. Genetics (Neuropsychiatric) 54, 21–26.
Jönsson, E., Lannfelt, L., Sokoloff, P., Schwartz, J.-C., and Sedvall, G. (1993) Lack of association in a Bal-I polymorphism in the dopamine D3 receptor gene in schizophrenia. Acta Psychiatr. Scand. 87, 345–347.
Laurent, C., Savoye, C., Samolyk, D., Meloni, R., Mallet, J., Campion, D., Martinez, M., d’ Amato, T., Bastard, C., and Dollfus, S. (1994) Homozygosity at the dopamine D3 receptor locus is not associated with schizophrenia. J. Med. Genetics 31, 260–264.
Nanko, S., Sasaki, T., Fukuda, R., Hattori, M., Dai, X. Y., Kazamatzuri, H., Kuwata, S., Juri, T., and Gill, M. (1993) A study of the association between schizophrenia and the dopamine D3 receptor gene. Hum. Genetics 92, 336–338.
Nimgaonkar, V. L., Zhang, X. R., Caldwell, J. G., Ganguli, R., and Chakravarti, A. (1993) Association study of schizophrenia with dopamine D3 receptor gene polymorphisms: probable effects of family history of schizophrenia? Am. J. Med. Genetics (Neuropsychiatric) 48, 214–217.
Nöthen, M. M., Cichon, S., Propping, P., Fimmers, R., Schwab, S. G., and Wildenauer, D. P. (1993) Excess of homozygosity at the dopamine D3 receptor gene not confirmed. J. Med. Genetics 30, 708–712.
Yang, L., Li, T., Wiese, C., Lannfelt, L., Sokoloff, P., Xu, C. T., Zeng, Z., Schwartz, J. C., and Moises, H. W. (1993) No association between schizophrenia and homozygosity at the D3 dopamine receptor gene. Am. J. Med. Genetics (Neuropsychiatric) 48, 83–86.
Nimgaonkar, V. L., Zhang, X. R., Brar, J., DeLeo, M., Hogge, W., Ganguli, R., and Chakravarti, A. (1995) Association between the dopamine D3 receptor gene locus and liability to schizophrenia, as well as its age of onset. Schizophrenia Res. 15 (1–2), 45.
Van Tol, H. H., Wu, C. M., Guan, H.-C., Ohara, K., Bunzow, J. R., Civelli, O., Kennedy, J., Seeman, P., Niznik, H. B., and Janovic, V. (1992) Multiple dopamine D4 receptor variants in the human population. Nature 358, 149–152.
Shaikh, S., Collier, D. A., Kerwin, R. W., Pilowsky, L. S., Gill, M., Xu, W.-M., and Thornton, A. (1993) Dopamine D4 receptor subtypes and response to clozapine. Lancet 341, 116.
Shaikh, S., Gill, M., Owen, M., Asherson, P., McGuffin, P., Nanko, S., Murray, R. M., and Collier, D. A. (1994) Failure to find linkage between a functional polymorphism in the dopamine D4 receptor gene and schizophrenia. Am. J. Med. Genetics 54, 8–I1.
Baldessarini, R. J., Gardner, D. M., and Garver, D. L. (1995) Conversions from clozapine to other antipsychotics. Arch. Gen. Psychiatry 52, 1071, 1072.
Seeman, P. (1992) Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7, 261–284.
Baldessarini, R. J. and Frankenburg, F. R. (1991) Clozapine—a novel antipsychotic agent. N. Engl. J. Med. 324, 746–754.
Lahti, R. A., Roberts, R. C., and Tamminga, C. A. (1995) D2-Family receptor distributions in human postmortem tissue: an autoradiographic study. NeuroReport 6, 2505–2512.
Murray, A. M., Hyde, T. M., Knable, M. B., Herman, M. M., Bigelow, L. B., Carter, J. M., Weinberger, D. R., and Kleinman, J. E. (1995) Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 15, 2186–2191.
O’Malley, K. L., Harmon, S., Tang, L., and Todd, R. D. (1992) The rat dopamine D4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system New Biologist 4, 137–146.
Reynolds, G. P. and Mason, S. L. (1994) Are striatal dopamine D4 receptors increased in schizophrenia? J. Neurochem. 63, 1576–1577.
Seeman, P., Guan, H.-C., and Van Tol, H. H. (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365, 441–445.
Amara, S. G. and Kuhar, M. J. (1993) Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16, 73–93.
Schloss, P., Wayser, W., and Betz, H. (1992) Neurotransmitter transporters: a novel family of integral plasma membrane proteins. FEBS Lett. 307, 76–80.
Persico, A. M., Wang, Z. W., Black, D. W., Andreasen, N. C., Uhl, G. R., and Crowe, R. R. (1995) The dopamine transporter gene and schizophrenia spectrum disorders: exclusion of close linkage. Am. J. Psychiatry 152, 134–136.
Joyce, J. N., Lexow, N., Bird, E. D., and Winokur, A. (1988) Organization of dopamine Di and D, receptors in human brain: receptor autoradiographic studies in Huntington’s disease and schizophrenia. Synapse 2, 546–557.
Owen, F., Crow, T. J., Poulter, M., Cross, A. J., Longden, A., and Riley, G. J. (1978) Increased dopamine receptor sensitivity in schizophrenia. Lancet 2, 223–225.
Lee, T. and Seeman, P. (1980) Elevation of brain neuroleptic/dopamine receptors in schizophrenia. Am. J. Psychiatry 137, 191–197.
Lee, T., Seeman, P., Tourtelotte, W. W., Farley, U. J., and Hornykiewicz, O. (1978) Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 274, 897–900.
Mackay, A. V., Bird, E. D., Spokes, E. G., Rossor, M., Iversen, L. L., Creese, I., and Snyder, S. H. (1980) Dopamine receptors and schizophrenia: drug effect or illness? Lancet 2, 915, 916.
Mackay, A. V., Iversen, L. L., Rossor, M., Spokes, E., Bird, E. D., Arregui, A., Creese, I., and Snyder, S. H. (1982) Increased brain dopamine and dopamine receptors in schizophrenia. Arch. Gen. Psychiatry 39, 991–997.
Reisine, T. D., Rossor, M., and Spokes, E. G. (1980) Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue, in Receptors for Neurotransmitters and Peptide Hormones ( Pepeu, G., Kuhar, M. J., and Enna, S. J., eds.), Raven, New York, pp. 443–450.
Cross, A. J., Crow, T. J., and Owen, F. (1981) 3H-Flupenthixol binding to postmortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors. Psychopharmacology 74, 122–124.
Toru, M., Nishikawa, T., Semba, J., Mataga, N., Takashima, M., Noda, K., and Shibuya, H. (1982) Increased dopamine metabolism in the putamen and caudate in schizophrenic patients, in Psychobiology of Schizophrenia ( Namba, M. and Kaiya, H., eds.), Pergamon, Oxford, UK, pp. 235–240.
Cross, A. J., Crow, T. J., Ferrier, I. N., Johnstone, E. C., McCreadie, R. M., Owen, F., Owens, D. G., and Pouter, M. (1983) Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. J. Neural Transm. 18 (Suppl.), 265–272.
Owen, F., Cross, A. J., and Crow, T. J. (1983) Ligand-binding studies in brains of schizophrenics, in Cell Surface Receptors ( Strange, P. G., ed.), Wiley, New York, pp. 163–183.
Pimoule, C., Schoemaker, H., Reynolds, G. P., and Langer, S. Z. (1985) [3H]SCH23390 labeled D, dopamine receptors are unchanged in schizophrenia and Parkinson’s disease. Eur. J. Pharmacol. 114, 235–237.
Mita, T., Hanada, S., Nishino, N., Kuno, T., Nakai, H., Yamadori, T., Mizoi, Y., and Tanaka, C. (1986) Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenia. Biol. Psychiatry 21, 1407–1414.
Hess, E. J., Bracha, H. S., Kleinman, J. E., and Creese, I. (1987) Dopamine receptor subtype imbalance in schizophrenia. Life Sci. 40, 1487–1497.
Seeman, P., Bzowej, N. H., Guan, H. C., Bergeron, C., Reynolds, G. P., Bird, E. P., Riederer, P., Jellinger, K., and Tourtellote, W. W. (1987) Human brain D, and D2 dopamine receptors in schizophrenia, Alzheimer’s, Parkinson’s, and Huntington’s diseases. Neuropsychopharmacology 1, 5–15.
Reynolds, G. P. and Gzudek, C. (1988) Status of the dopaminergic system in postmortem brain in schizophrenia. Psychopharmacol. Bull. 24, 345–347.
Kornhuber, J., Riederer, P., Reynolds, G. P., Beckmann, H., Jellinger, K., and Gabriel, E. (1989) 3H-Spiperone binding sites in postmortem brains from schizophrenic patients: relationship to drug treatment, abnormal movements, and positive symptoms. J. Neural Transm. 75, 1–10.
Seeman, P., Niznik, H. B., Guan, H.-C., Booth, G., and Ulpian, C. (1989) Link between D, and D2 dopamine receptors is reduced in schizophrenia and Hunting-ton’s diseased brain. Proc. Natl. Acad. Sci. USA 86, 10,156–10, 160.
Mamelak, M., Chiu, S., and Mishra, R. K. (1993) High and low affinity states of dopamine D, receptors in schizophrenia. Eur. J. Pharmacol. 233, 175, 176.
Schmauss, C., Hartounian, V., Davis, K. L., and Davidson, M. (1993) Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc. Natl. Acad. Sci. USA 90, 8942–8946.
Knable, M. B., Hyde, T. M., Herman, M. M., Carter, J. M., Bigelow, L., and Kleinman, J. E. (1994) Quantitative autoradiography of dopamine D, receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol. Psychiatry 36, 827–835.
Kessler, R. M., Whetsell, W. O., Sib Ansari, M. S., Tamminga, C. A., and Mason, N. S. (1995) [125I]Epidepride binding in postmortem brain of schizophrenic subjects. Schizophrenia Res. 15(1–2) 62.
Joyce, J. N., Gurevich, E. V., Kung, H. F., Kung, M.-P., Bordelon, Y., Shapiro, P., Arnold, S. E., and Gur, R. E. (1995) Dopamine D3 receptors are elevated in schizophrenic brain and decreased by neuroleptic treatment. Schizophrenia Res. 15 (1 2), 61.
Crow, T. J., Cross, A. J., Johnstone, E. C., Owen, F., Owens, D. G., and Waddington, J. L. (1982) Abnormal involuntary movements in schizophrenia: are they associated with changes in dopamine receptors? J. Clin. Psychopharmacol. 2, 336–340.
Crow, T. J., Owen, F., Cross, A. J., Ferrier, N., Johnstone, E. C., McCreadie, R. M., Owens, D. G., and Poulter, M. (1981) Neurotransmitter enzymes and receptors in postmortem brain in schizophrenia: evidence that an increase in D2 dopamine receptors in associated with the type I syndrome, in Transmitter Biochemistry of Human Brain Tissue ( Riederer, P. and Usdin, E., eds.), MacMillan, London, pp. 85–96.
Seeman, P. and Niznik, H. B. (1990) Dopamine receptors and transporters in Parkinson’s disease and schizophrenia. FASEB J. 4, 2737–2744.
Seeman, P., Ulpian, C., Bergeron, C., Riederer, P., Jellinger, K., Gabriel, E., Reynolds, G. P., and Tourtelotte, W. W. (1984) Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 225, 728–731.
Baldessarini, R. J., and Tarsy, D. (1979) Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. Intl. Rev. Neurobiol. 21, 1–45.
Andreasen, N. C., Carson, R., Diksic, M., Evans, A., Farde, L. O., Gjedde, A., Hakin, A., Lal, S., Nair, N., Sedvall, G., Tune, L., and Wong, D. F. (1988) Workshop on schizophrenia, PET and dopamine D2 receptors in the human neostriatum. Schizophrenia Bull. 14, 471–484.
Baldessarini, R. J., Kula, N. S., Campbell, A., Bakthavachalam, V., Yuan, J., and Neumeyer, J. L. (1992) Prolonged D2 antidopaminergic activity of alkylating and nonalkylating derivatives of spiperone in rat brain. Mol. Pharmacol. 42, 856–863.
Memo, M., Kleinman, J. E., and Hanbauer, I. (1983) Coupling of dopamine DI recognition sites with adenylate cyclase in nuclei accumbens and caudatus of schizophrenics. Science 221, 1304–1307.
Lévesque, D., Martres, M.-P., Diaz, J., Griffon, N., Lammers, C. H., Sokoloff, P., and Schwartz, J.-C. (1995) A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. USA 92, 1719–1723.
Gelbard, H., Teicher, M. H., Gallitano, A., Marsh, E. R., Zorc, J., Faedda, G., and Baldessarini, R. J. (1990) Dopamine DI receptor development depends on endogenous dopamine. Dey. Brain Res. 56, 137–140.
Hitri, A., Casanova, M. F., Kleinman, J. E., Weinberger, D. R., and Wyatt, R. J. (1995) Age-related changes in [3H]GBR-12935 binding site density in the prefrontal cortex of controls and schizophrenics. Biol. Psychiatry 37, 175–182.
Madras, B. K., Spealman, R. D., Fahey, M. A., Neumeyer, J. L., Saha, J. K., and Milius, R. A. (1989) Cocaine receptors labeled by [3H]213-carbomethoxy-313-(4-fluorophenyl)tropane. Mol. Pharmacol. 36 518–524.
Neumeyer, J. L., Wang, S., Milius, R. A., Baldwin, R. M., Zea-Ponce, Y., Hoffer, P. B., Sybirska, E., Al-Tairiti, M., Chamey, D. S., Malison, R. T., Lamelle, M., and Innis, R. B. (1991) [l231]2ß-Carbomethoxy-313-(4-iodophenyl)-tropane: high affinity SPECT radiotracer for monoamine reuptake sites in brain. J. Med. Chem. 34, 3144–3146.
Janowsky, A., Vocci, F., Berger, P., Angel, I., Zelnck, N., Kleinman, J. E., Skolnick, P., and Paul, S. M. (1987) [3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson’s disease. J. Neurochem. 49, 617–621.
Czudek, C. and Reynolds, G. P. (1989) [3H]GBR-12935 binding to the dopamine uptake sites in postmortem brain tissue in schizophrenia. J. Neural Transm. 77, 227–230.
Bogerts, B. (1991) The neuropathology of schizophrenia: pathophysiologic and neurodevelopmental implications, in Fetal Neural Development and Adult Schizophrenia ( Mednick, S. A., Cannon, T. D., and Barr, C. E., eds.), Cambridge University Press, London, pp. 153–173.
Shapiro, R. M. (1993) Regional neuropathology in schizophrenia: where are we; where are we going? Schizophrenia Res. 10, 187–239.
Trojanowski, J. Q. and Arnold, S. E. (1995) In pursuit of the molecular neuropathology of schizophrenia. Arch. Gen. Psychiatry 52, 274–276.
Ariano, M. A. and Sibley, D. R. (1994) dopamine receptor distribution in the rat CNS: elucidation using antipeptide antisera directed against DtA and D3 subtypes. Brain Res. 649, 95–110.
Boundy, V. A., Luedtke, R. R., Gallitano, A. L., Smith, J. E., Filtz, T. M., Kallen, R. G., and Molinoff, P. B. (1993) Expression and characterization of the rat D3 dopamine receptor: pharmacologic properties and development of antibodies. J. Pharmacol. Exp. Ther. 264, 1002–1011.
Baron, J. C., Comar, D., Farde, L. O., Martinot, J. L., and Mazoyer, B. (eds.) (1991) Brain Dopaminergic Systems: Imaging with Positron Tomography. Kluwer, Dordrecht, Germany.
Farde, L. O., Nordström, A.-L., Eriksson, L., Halldin, C., and Sedvall, G. (1990) Comparison of methods used with [“C]raclopride and [”C]N-methylspiperone for the PET-determination of central D, dopamine receptors. Clin. Neuropharmacol. 13(Suppl. 2 ), 87, 88.
Konig, P., Benzer, M. K., and Fritsche, H. (1991) SPECT technique for visualization of cerebral dopamine D, receptors. Am. J. Psychiatry 148, 1607, 1608.
Reba, R. C. (1993) PET and SPECT: opportunities and challenges for psychiatry. J. Clin. Psychiatry 54 (Suppl. 11), 26–32.
Ring, H. A. (1995) the value of positron emission tomography in psychopharmacology (1995) Hum. Psychopharmacology 10, 79–87.
Sedvall, G. (1992) The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology 7, 41–54.
Verhoeff, N. P. (1991) Pharmacological implications for neuroreceptor imaging. Eur. J. Nucl. Med. 18, 482–502.
Weinberger, D. R. (1993) SPECT imaging in psychiatry: introduction and overview. J. Clin. Psychiatry 54 (Suppl. 11), 3–5.
Wong, D. F. (1992) PET studies of neuroreceptors in schizophrenia: commentary on the current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology 7, 69–72.
Billings, J. J., Kung, M.-P., Chumpradit, S., Mozley, D., Alavi, A., and Kung, H. F. (1992) Characterization of radioiodinated TISCH: a high-affinity and selective ligand for mapping CNS D dopamine receptor. J. Neurochem. 58 277–286.
Kung, H. F. (1993) SPECT and PET ligands for CNS imaging. RBI Neurotransmissions 9 (4), 1–6.
Kung, M.-P., Kung, H. F., Billings, J., Yang, Y., Murphy, R. A., and Alavi, A. (1990) Characterization of IBF as a new selective dopamine Dz receptor imaging agent. J. Nucl. Med. 31, 648–654.
Mazière, B., Coenen, H. H., Halldin, C., Nâgren, K., and Pike, V. W. (1992) PET radioligands for dopamine receptors and reuptake sites: chemistry and biochemistry. Nucl. Med. Biol. 19, 497–512.
Stöcklin, G. (1992) Tracers for metabolic imaging of brain and heart. Eur. J. Nucl. Med. 19, 527–551.
Wong, D. F., Wilson, A. A., Chen, C., Minkin, E., Dannals, R. F., Ravert, H. T., Sanchez-Roa, P., Villemagne, V., and Wagner, J. N., Jr. (1992) In vivo studies of [’25I]iodobenzamide and [“C]iodobenzamide: a ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D2 dopamine receptors. Synapse 12, 236–241.
Farde, L. O., Nyberg, S., Oxenstierna, G., Nakashima, Y., Halldin, C., and Ericsson, B. (1995) Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J. Clin. Psychopharmacol. 15 (Suppl. 1), 19–23.
Crawley, C. W., Crow, T. J., Johnstone, E. C., Oldland, S. R., Owen, F., Owens, D. G., Smith, T., Veall, N., and Zanelli, G. D. (1986) Uptake of 76Br-spiperone in the striata of schizophrenic patients and controls. Nucl. Med. Commun. 7, 599–607.
Wong, D. F., Wagner, H. N., Jr., Tune, L. E., Dannals, R. F., Pearlson, G. D., Links, J. M., Tamminga, C. A., Broussolle, E. P., Ravert, H. T., Wilson, A. A., Toung, J. K., Malat, J., Williams, J. A., O’Tauma, L. A., Snyder, S. H., Kuhar, M. J., and Gjedde, A. (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naïve schizophrenics. Science 234, 1558–1563.
Wong, D. F., Singer, H., Pearlson, G., Tune, L., Ross, C., Villemagne, V., Dannals, R. F., Links, J. M., Wilson, A., Ravert, H., Wagner, H. N., Jr., and Gjedde, A. (1988) D2 dopamine receptors in Tourette’s syndrome and manic-depressive illness. J. Nucl. Med. 29, 820, 821.
Blin, J., Baron, J. C., Cambon, H., Bonnet, A. M., DuBois, D., Loc’h, C., Mazière, B., and Agid, Y. (1989) Striatal dopamine D2 receptors in tardive dyskinesia: PET study. J. Neurol. Neurosurg. Psychiatry 52, 1248–1252.
Martinot, J.-L., Peron-Magna, P., Huret, J.-D., Mazoyer, B., Baron, J.-C., Boulenger, J.-P., Loc’h, C., Mazière, B., Caillard, V., Loo, H., and Syrota, A. (1990) Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. Am. J. Psychiatry 147, 44–50.
Martinot, J.-L., Paillère-Martinot, M. L., Loc’h, C., Hardy, P., Poirier, M. F., Mazoyer, B., Beaufils, B., Mazière, B., Allilaire, J. F., and Syrota, A. (1991) The estimated density of D2 striatal receptors in schizophrenia: a study with positron emission tomography and [76Br]bromolisuride. Br. J. Psychiatry 158, 346–350.
Nordström, A.-L., Farde, L. O., Pauli, S., Litton, J.-E., and Halldin, C. (1992) PET analysis of central [“C]raclopride binding in healthy young adults and schizophrenic patients: reliability and age effects. Hum. Psychopharmacology 7, 157–165.
Suhara, T., Nakayama, K., Inoue, O., Fukuda, H., Shimizu, M., Mori, A., and Tateno, Y. (1992) D dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 106, 14–18.
Pearlson, G. D., Tune, L. E., Wong, D. F., Aylward, E. H., Barta, P. E., Powers, R. E., Tien, A. Y., Chase, G. A., Harris, G. J., and Rabins, P. V. (1993) Quantitative D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia. Schizophrenia Bull. 19, 783–795.
Tune, L. E., Wong, D. F., Pearlson, G., Strauss, M., Young, T., Shaya, E. K., Dannals, R. F., Wilson, A. A., Ravert, H. T., Sapp, J., Cooper, T., Chase, G. A., and Wagner, H. N., Jr. (1993) Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with “C-N-methylspiperone. Psychiatry Res. 49, 219–237.
D’haenen, H. A. and Bossuyt, A. (1994) Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol. Psychiatry 35, 128–132.
Ebert, D., Feistel, H., Kaschka, W., Barocka, A., and Pirner, A. (1994) Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation—preliminary results. Biol. Psychiatry 35, 880–885.
Hietala, J., Syvälahti, E., Vuorio, K., Nägren, K., Lehikoinen, P., Ruotsalainen, U., Räkkäpläinen, V., Lehtinen, V., and Wegelius, U. (1994) Striatal D2 dopamine receptor characteristics in neuroleptic-naïve schizophrenic patients studied with positron emission tomography. Arch. Gen. Psychiatry 51, 116–123.
Martinot, J.-L., Paillère-Martinot, M. L., Loc’h, C., Lecrubier, Y., Dao-Castellana, M. H., Aubin, F., Allilaire, J. F., Mazoyer, B., Mazière, B., and Syrota, A. (1994) Central D2 receptors and negative symptoms of schizophrenia. Br. J. Psychiatry 164, 27–34.
Pilowsky, L. S., Costa, D. C., Ell, P. J., Murray, R. M., Verhoeff, N. P., and Kerwin, R. W. (1994) D2 dopamine receptor binding in the basal ganglia of antipsychoticfree schizophrenic patients: an t23I-IBZM single photon emission computerized tomographic study. Br. J. Psychiatry 164, 16–26.
Knable, M. B., Gonzalez, J., Coppola, R., Jones, D. W., Nawroz, S., Gorey, J., and Weinberger, D. R. (1995) 123I-IBZM SPECT in neuroleptic-free schizophrenic patients. Schizophrenia Res. 15(1–2) 88.
Tune, L. E., Wong, D. F., and Pearlson, G. D. (1992) Elevated dopamine D2 receptor density in 23 schizophrenic patients: a positron emission tomography study with [“C]N-methylspiperone. Schizophrenia Res. 6, 147.
Farde, L. O., Wiesel, F.-A., Hall, H., Halldin, C., Stone-Elander, S., and Sedvall, G. (1987) No D2 receptor increase in PET study of schizophrenia. Arch. Gen. Psychiatry 44, 671–675.
Farde, L. O., Wiesel, F.-A., Stone-Elander, S., Halldin, C., Nordstrom, A.-L., Hall, H., and Sedvall, G. (1990) D2 dopamine receptors in neuroleptic-naïve schizophrenic patients. Arch. Gen. Psychiatry 47, 213–219.
Hall, H., Wedel, I., Halldin, C., Kopp, J., and Farde, L. (1990) Comparison of the in vitro receptor binding properties of [3H]-N-methylspiperone and [3H]raclopride to rat and human brain membranes. J. Neurochem. 55, 2048–2057.
Logan, J., Dewey, S. L., Wolf, A. P., Fowler, J. S., Brodie, J. D., Angrist, B., Wolkow, N. D., and Gatley, S. J. (1991) Effects of endogenous dopamine on measures of [’SF]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons. Synapse 9, 195–207.
Young, L. T., Wong, D. F., Goldman, S., Minkin, E., Chen, C., Matsumura, K., Scheffel, U., and Wagner, H. N., Jr. (1991) Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain. Synapse 9, 188–194.
TenBrink, R. E. and Huff, R. M. (1994) Recent advances in dopamine D3 and D4 receptor ligands and pharmacology. Ann. Rep. Med. Chem. 2, 43–52.
Dewey, S. L., Logan, J., Wolf, A. P., Brodie, J. D., Angrist, B., Fowler, J. S., and Volkow, N. D. (1991) Amphetamine induced decreases in [18F]N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET). Synapse 7, 324–327.
Dewey, S. L., Smith, G. S., Logan, J., Brodie, J. D., Simkowitz, P., MacGregor, R. R., Fowler, J. S., Volkow, N. D., and Wolf, A. P. (1993) Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc. Natl. Acad. Sci. USA. 90, 11,816–11, 820.
Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., Dyve, S. E., Etienne, P., Evans, A. C., Lal, S., Shevell, M., Savard, G., Wong, D. F., Chouinard, G., and Gjedda, A. (1994) Elevated DOPA decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. USA 91, 11,651–11, 654.
Wong, D. F., Pearlson, G. D., Young, L. T., Singer, H., Villemagne, V., Tune, L., Ross, C., Dannals, R. F., Links, J. M., Chan, B., Wilson, A. A., Ravert, H. T., Wagner, H. N., Jr., and Gjedde, A. (1989) D2 dopamine receptors are elevated in neuropsychiatric disorders other than schizophrenia. J. Cereb. Blood FlowMetabol. 9 (Suppl. 1), 593S.
Chabriat, H., Levasseur, M., Vidailhet, M., Loc’h, C., Mazière, B., Bourguignon, M. H., Bonnet, A. M., Zilbovicius, M., Raynaud, C., Agid, Y., Syrota, A., and Samson, Y. (1992) In vivo SPECT imaging of D2 receptor with 1231-iodolisuride: results in supranuclear palsy. J. Nucl. Med. 33, 1481–1485.
Rutgers, A. W., Lakke, J. P., Paans, A. M., Vaalburg, W., and Korf, J. (1987) Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography (PET). J. Neurol. Sci. 80, 237–248.
Sawle, G. V., Playford, E. D., Brooks, D. J., Quin, N., and Fackowiack, R. S. (1993). Asymmetrical presynaptic and postsynaptic changes in the striatal dopamine projection in DOPA-naïve parkinsonism. Brain 116, 853–867.
Carroll, F. I., Lewin, A. H., Boja, J. W., and Kuhar, M. J. (1992) Cocaine receptor: biochemical characterization and structure—activity relationships of cocaine analogs at the dopamine transporter. J. Med. Chem. 35, 969–981.
Frost, J. J., Rosier, A. J., Reich, S. G., Smith, J. S., Ehlers, M. D., Snyder, S. H., Ravert, H. T., and Dannals, R. F. (1993) Positron emission tomographic imaging of the dopamine transporter with [“C] WIN-35428 reveals marked declines in mild Parkinson’s disease. Ann. Neurology 34, 423–431.
Innis, R. B., Seibyl, J. P., Scanley, B. E., Laruelle, M., Abi-Dargham, A., Wallace, E., Baldwin, R. M., Zea-Ponce, Y., Zoghbi, S., Wang, S., Gao, Y., Neumeyer, J. L., Charney, D. S., Hoffer, P. B., and Marek, K. L. (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal monoamine transporters in Parkinson’s disease. Proc. Natl. Acad. Sci. USA 90, 11,965–11, 969.
Farde, L. O., Nordström, A.-L., Wiesel, F.-A., Pauli, S., Halldin, C., and Sedvall, G. (1992) Positron emission tomographic analysis of central D, and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch. Gen. Psychiatry 49, 538–544.
Farde, L. O., Wiesel, F.-A., Halldin, C., and Sedvall, G. (1988) Central D,-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 45, 71–76.
Smith, M., Wolf, A. P., Brodie, J. D., Arnett, C. D., Barouche, F., Shiue, C.-Y., Fowler, J. S., Russell, J. A., MacGregor, R. R., Wolkin, A., Angrist, B., Rotrosen, J., and Peselow, E. (1988) Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D2 receptor occupancy in schizophrenic patients. Biol. Psychiatry 23, 653–663.
Cambon, H., Baron, J. C., Boulenger, J. P., Loc’h, C., Zarifian, E., and Mazière, B. (1987) In vivo assay for neuroleptic receptor binding in the striatum. Br. J. Psychiatry 151, 824–830.
Wolkin, A., Brodie, J. D., Barouche, F., Rotrosen, J., Wolf, A. P., Smith, M., Fowler, J. S., and Cooper, T. B. (1989) Dopamine receptor occupancy and plasma haloperidol levels. Arch. Gen. Psychiatry 46, 482–484.
Brücke, T., Roth, J., Podreka, I., Strobl, R., Wegner, S., and Asenbaum, S. (1992) Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet 339, 497.
Nordström, A.-L., Farde, L. O., Wiesel, F.-A., Forslund, K., Pauli, S., Halldin, C., and Uppfeldt, G. (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenia patients. Biol. Psychiatry 33, 227–235.
Nordström, A.-L., Farde, L. O., and Halldin, C. (1992) Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 106, 433–438.
Nordström, A.-L., Farde, L. O., and Halldin, C. (1993) High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110, 365–367.
Baldessarini, R. J., Cohen, B. M., and Teicher, M. H. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch. Gen. Psychiatry 45, 79–91.
Baron, J. C., Martinot, J. L., Cambon, H., Boulenger, J. P., Poirir, M. F., Caillard, V., Blin, J., Huret, J. D., Loc’h, C., and Mazière, B. (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99, 463–472.
Nyberg, S., Farde, L. O., Halldin, C., Dahl, M.-L., and Bertilson, L. (1995) D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am. J. Psychiatry 152, 173–178.
Pickar, D., Su, T.-P., Coppola, R., Lee, C. S., Hsiao, J. K., Breier, A., and Weinberger, D. R. (1995) D2 occupancy and dopamine release determined by’ 23I-IBZM SPECT following clozapine dose reduction. Schizophrenia Res. 15 (1–2), 96.
Pilowsky, L. S., Costa, D. C., Ell, P. J., Murray, R. M., Verhoeff, N. P., and Kerwin, R. W. (1992) Clozapine, single photon emission tomography, and the D 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340, 199–202.
Cohen, B. M., Tsuneizumi, T., Baldessarini, R. J., Campbell, A., and Babb, S. (1992) Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology 108, 338–344.
Hubbard, J. W., Ganes, D., and Midha, K. K. (1987) Prolonged pharmacologic activity of neuroleptic drugs. Arch. Gen. Psychiatry 44, 99, 100.
Schotte, A., Janssen, P. F., Gommeren, W., Luyten, W. H., and Leysen, J. E. (1992) Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo. Eur. J. Pharmacol. 218, 373–375.
Meltzer, H. Y. (ed.) (1992) Novel Antipsychotic Drugs. Raven, New York.
Sokoloff, P., Martres, M. P., Giros, B., Bouthenet, M. L., and Schwartz, J.-C. (1992) The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem. Pharmacol. 43, 659–666.
Baldessarini, R. J., Kula, N. S., McGrath, C., Kebabian, J. W., and Neumeyer, J. L. (1993) Isomeric selectivity of D3 dopamine receptors. Eur. J. Pharmacol. 239, 269, 270.
Chumpradit, S., Kung, M.-P., and Kung, H. F. (1993) Synthesis and optical resolution of (R) and (S)-trans-7-hydroxy-2-[N-propyl-N-(3’-iodo’-2’-propenyl) amino]tetralin: a new D3 dopamine receptor ligand. J. Med. Chem. 36, 4308–4312.
DeWald, H. A., Heffner, T. G., Jaen, J. C., Lustgarten, D. M., McPhail, A. T., Meltzer, L. T., Pugsley, T. A., and Wise, L. D. (1990) Synthesis and dopamine agonist properties of (±)-trans-3,4,4a,1Ob-tetrahyro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol and its enantiomers. J. Med. Chem. 33, 445–450.
Sokoloff, P., Giros, B., Martres, M. P., Bouthenet, M. L., and Schwartz, J.-C. (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347, 146–151.
Waters, N., Lagerkvist, S., Löfberg, L., Piercey, M., and Carlsson, A. (1993) The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)UH232: a microdialysis study. Eur. J. Pharmacol. 242, 151–163.
Burris, K. D., Filtz, T. M., Chumpradit, S., Kung, M.-P., Foulon, C., Hensler, J. G., Kung, H., and Molinoff, P. B. (1994) Characterization of [’ 25I]-trans-7-hydroxy-2[(N-propyl-N-3’-iodo-2’-propenyl)amino]tetralin binding to dopamine D3 receptors in rat olfactory tubercle. J. Pharmacol. Exp. Ther. 268, 935–942.
Booth, R. G., Baldessarini, R. J., and Marsh, E. R. (1994) Effects of a D3-selective aminotetralin on dopamine metabolism in rat brain regions in vitro and in vivo. Brain Res. 662, 283–288.
Malmberg, A., Jackson, D. M., Eriksson, A., and Mohell, N. (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol. Pharmacol. 43, 749–754.
Lahti, R. A., Evans, D. L., Stratman, N. C., and Figur, L. M. (1993) Dopamine D, vs. D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur. J. Pharmacol. 236, 483–486.
Seeman, P. and Van Tol, H. H. (1993) Dopamine D, receptors bind inactive (+)aporphines, suggesting a neuroleptic role: sulpiride not stereoselective. Eur. J. Pharmacol. 233, 173, 174.
Campbell, A., Yeghiayan, S., Baldessarini, R. J., and Neumeyer, J. L. (1991) Selective antidopaminergic effects of S(+) N-n-propylnoraporphines in limbic vs. extrapyramidal sites in rat brain: comparisons with typical and atypical anti-psychotic agents. Psychopharmacology 103, 323–329.
Kula, N. S., Baldessarini, R. J., Kebabian, J. W., and Neumeyer, J. L. (1994) S(+)aporphines are not selective for human D3 dopamine receptors. Cell. Mol. Neurobiology 14, 185–191.
Baldessarini, R. J., Campbell, A., Ellingboe, J., Zong, R., and Neumeyer, J. L. (1994) Effects of aporphine isomers on rat prolactin. Neurosci. Lett. 176, 269–271.
Campbell, A., Baldessarini, R. J., and Neumeyer, J. L. (1993) Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine. Psychopharmacology 111, 351–358.
Baldessarini, R. J. and Tarazi, F. I. (1996) Brain dopamine receptors: a primer on their current status, basic and clinical. Harvard Rev. Psychiatry 3, 301–325.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Baldessarini, R.J. (1997). Dopamine Receptors and Clinical Medicine. In: Neve, K.A., Neve, R.L. (eds) The Dopamine Receptors. The Receptors. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4757-2635-0_15
Download citation
DOI: https://doi.org/10.1007/978-1-4757-2635-0_15
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-2637-4
Online ISBN: 978-1-4757-2635-0
eBook Packages: Springer Book Archive